AXL-inhibiting drugs might reverse EMT and sensitize resistant tumors to ICIs (21), and are currently being tested together with ICIs in NSCLC patients in clinical trials (NCT05469178, NCT03184571). Here, AXL is linked to non-small cell lung carcinoma.